The funding will be used to support the upcoming launch of the Teal Wand™, which is currently under FDA review and on track to be the US market's first FDA-approved at-home self-collect cervical cancer screening device. This new capital brings Teal Health's funding to $23 million to date as the company accelerates its product development and readies go-to-market plans.

This latest investment, led by Emerson Collective and Forerunner with continued support from existing investors, such as Serena Ventures, Metrodora, and new partner Labcorp, marks a pivotal step for Teal Health. It builds on the company's recent achievements, including a $1.68 million Small Business Innovation Research (SBIR) grant from the National Cancer Institute and FDA Breakthrough Device Designation.

Teal Health is on a mission to design a better healthcare experience for women - starting with cervical cancer screenings. By creating the option for a woman to screen for cervical cancer from the comfort of home and providing telehealth follow-up, Teal can increase access to this life-saving cancer screening. Teal Health is a member of the Cervical Cancer Roundtable, a joint collaboration between the American Cancer Society and the Biden Cancer Moonshot, a coalition of industry leaders with the goal of eliminating cervical cancer as a public health concern in the US.